Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

293 results about "Messenger RNA" patented technology

Messenger RNA (mRNA) is a large family of RNA molecules that convey genetic information from DNA to the ribosome, where they specify the amino acid sequence of the protein products of gene expression. The RNA polymerase enzyme transcribes genes into primary transcript mRNA (known as pre-mRNA) leading to processed, mature mRNA. This mature mRNA is then translated into a polymer of amino acids: a protein, as summarized in the central dogma of molecular biology.

Methods of simultaneously identifying or quantifying capping and tailing modifications of messenger RNA

PCT designated stage expiredWO2024256674A1HydrolasesMicrobiological testing/measurementBase JAssay
The present disclosure provides, among other things, single sample multi-attribute methods of simultaneously identifying and / or quantifying RNA capping and tailing modifications. The present disclosure provides, among other things, oligonucleotides comprising RNA and DNA bases that are complementary to the 5' and 3' ends of RNA. Provided herein is a method of manufacturing RNA for therapeutic use having a quantified percentage of capped and untailed mRNA, and a specified poly A tail length and polydispersity. Also provided herein is a quality control assay for a manufacturing lot.
Owner:SANOFI SA(FR)

Multivalent influenza mRNA vaccines

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNAs) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) than the mRNA encoding the influenza B virus, and methods of eliciting an immune response by administering said compositions. In particular, the disclosures relate to mRNA encoding these antigens formulated in a lipid nanoparticle (LNP).
Owner:SANOFI PASTEUR INC

Compositions and methods for the treatment of ornithine transcarbamylase deficiency

The present disclosure describes compositions and methods for treating ornithine transcarbamylase (OTC) deficiency. The compositions include a lipid formulation and messenger RNA (mRNA) encoding an OTC enzyme. The lipid formulations can comprise an ionizable cationic lipid in a lipid nanoparticle encapsulating the mRNA.
Owner:ARCTURUS THERAPEUTICS INC

Method, model, device, equipment and medium for predicting stability of messenger RNA

The invention relates to the technical field of biological information, and discloses a messenger RNA stability prediction method, model, device, equipment and medium, the method comprises the following steps: obtaining target sequence information of a target messenger RNA; acquiring at least two of the following target feature information based on the target sequence information by using a feature extraction module in the messenger RNA stability prediction model: first sequence feature information, Kozak sequence feature information, Motif attention feature information and manual feature information; and predicting the stability of the target messenger RNA based on the target feature information by using a prediction head in the messenger RNA stability prediction model. According to the method, the mRNA stability is predicted by fusing the universal sequence feature of the mRNA, the Kozak sequence feature of the learnable position weight, the Motif attention feature based on the hash k-mer and the manual feature, and the accuracy of mRNA stability prediction is improved.
Owner:BEIJING YUEKANGKECHUANG PHARM TECH CO LTD

Compositions and methods for suppressing intracellular synthesis of the beta subunit of human chorionic gonadotropin

ActiveUS12590308B1Organic active ingredientsTumor/cancer cellsBase JHCG - Human chorionic gonadotropin
A composition of matter includes an antisense phosphorodiamidate morpholino oligomer (MO) that includes an MO base sequence. The MO base sequence is arranged to bind a corresponding complementary base sequence of messenger RNA (mRNA) transcribed from one or more genes for the beta subunit of human chorionic gonadotropin (hCG-β). An inventive method, for suppressing intracellular synthesis of a beta subunit of human chorionic gonadotropin (hCG-β), includes introducing such an MO into one or more cells.
Owner:JAMES SUMMERTON LIVING TRUST DATED MAY 15 2008

Method for treating interferonopathies

Methods for interfering or controlling IFN induction, IFN production and / or IFN activity are disclosed, harnessing viral mechanisms for evading or suppressing host anti-viral immune reactions. These methods comprise administration of one or more viral messenger RNAs (mRNAs) coding for proteins or peptides that control or interfere with signal transduction upstream and / or downstream of IFN induction, thereby providing a means for preventing or treating diseases, disorders or conditions associated with increased IFN production, such as cancer, autoimmune diseases, inflammatory diseases and interferonopathies.
Owner:IMMUNOBEL THERAPEUTICS LTD

Lipid nanoparticles comprising an imidazolium-based cationic lipid

The present invention relates to compositions for in vitro and in vivo delivery of nucleic acids, in particular messenger RNAs (mRNAs), into a target cell and their applications. The present invention is directed to a composition comprising (A) at least one nucleic acid and (B) at least one lipid nanoparticle (LNP) comprising (i) at least one ionizable lipid; (ii) at least one phospholipid; (iii) at least one sterol, especially neutral sterol; (iv) at least one poly(ethyleneglycol)-lipid (PEG-lipid); and (v) an imidazolium-based cationic lipid of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9, Y and A− are as defined in the description. The present invention also relates to a method for in vitro or in vivo transfection of live cells and uses of said composition.
Owner:SARTORIUS POLYPLUS

DsRNA insecticide for preventing and treating thrips and preparation method of dsRNA insecticide

The invention relates to a dsRNA insecticide for preventing and treating thrips and a preparation method of the dsRNA insecticide. Belongs to the field of biotechnology and agricultural application. The dsRNA insecticide for preventing and treating the thrips is a preparation taking dsRNA as an effective component, and the dsRNA is of a double-stranded RNA structure containing a positive-sense strand and an antisense strand; the nucleotide sequence of the positive-sense strand is as shown in SEQ ID NO. 1, SEQ ID NO. 3, SEQ ID NO. 5, SEQ ID NO. 7, SEQ ID NO. 9 or SEQ ID NO. 11. The invention proves that dsACT and dsVATB can cause degradation of messenger RNA (Ribonucleic Acid) of ATP (Adenosine Triphosphate) enzyme coding genes in thrips and reduce the expression level of related genes; laboratory test and field efficacy test results jointly show that after the dsRNA insecticide is sprayed, the growth and development of the thrips are affected, individual death is further caused, and the achievement lays a good theoretical and application foundation for prevention and treatment of the thrips.
Owner:SINOCHEM NINGBO CHEM

Novel lipid nanoparticle formulations for delivery of nucleic acids

The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids as defined herein, related pharmaceutical compositions or vaccines for use in human medicine or veterinary medicine, in particular for the treatment and / or prevention of cancer diseases.
Owner:CUREVAC SE

Lipid nanoparticle, and methods of use thereof

The present disclosure provides lipid nanoparticles for delivery of a payload (e.g., messenger RNA (mRNA)) to the heart. For example, lipid nanoparticle comprises an acid-degradable polyethylene glycol (PEG)-lipid (ADP) having molecular weight in the range of 1000 to 4500 Da. In some embodiments, the acid-degradable polyethylene glycol (PEG)-lipid is present in a mole percentage of about 1% to about 25% of the total lipids. The disclosure also encompasses methods for delivery of messenger RNA (mRNA) for transfection of cells, methods of treatment, as well as kits thereof.
Owner:RGT UNIV OF CALIFORNIA

Methods and compositions for messenger RNA purification

The present invention provides, among other things, methods for purifying mRNA, which involves removing impurities from a messenger RNA preparation synthesized by large scale invitro transcription process (IVT), by precipitating the IVT-synthesized mRNA in a buffer comprising a denaturing salt in combination with a reducing agent, followed by capturing the precipitated mRNA and dissolving the captured mRNA into a solution to obtain purified mRNA.
Owner:TRANSLATE BIO INC

Methods and compositions for analyzing messenger RNA

PCT designated stage expiredWO2025012461A1Microbiological testing/measurementMessenger RNAGenetics
The present disclosure is directed to a method of determining the presence of at least one messenger RNA (mRNA) molecule in a composition, which method comprises: (a) reverse transcribing the at least one mRNA molecule to obtain a template comprising at least one first strand of complementary DNA (cDNA); (b) generating at least one double-stranded cDNA molecule from the template; (c) amplifying the at least one double-stranded cDNA molecule; (d) digesting the at least one amplified double-stranded cDNA molecule with at least one restriction enzyme to obtain test cDNA fragments; (e) separating the test cDNA fragments, to thereby form a test cDNA fragment pattern; and (f) comparing the test cDNA fragment pattern with a control cDNA fragment pattern, wherein the at least one mRNA molecule is present in the composition when the test cDNA fragment pattern comprises the control cDNA fragment pattern. Methods of quantitating and / or assessing the integrity of at least one mRNA molecule in a composition, a process of manufacturing a composition comprising at least one mRNA molecule and primer pairs for use in the present methods are also disclosed.
Owner:SANOFI PASTEUR INC

Anti-vibration device for transporting a substance such as a messenger RNA vaccine

A case for transporting a substance such as a messenger RNA vaccine, including a container, a damping material contained in the container and a storage structure immersed in the damping product, the storage structure forming cavities for receiving syringes containing said substance.
Owner:CENT NAT DE LA RECH SCI (C N R S) +1

A method and apparatus for codon sequence optimization of human albumin

ActiveCN121506296BMessenger RNAHuman albumin
This application provides a method and apparatus for optimizing the codon sequence of human albumin, belonging to the field of data processing technology. Addressing the current problems of low synthesis efficiency and scarcity of human albumin drugs, it allows for the grouping of large datasets of human albumin amino acid sequences. An improved genetic optimization algorithm is then used to optimize the corresponding messenger RNA item by item, ultimately obtaining the optimal second target messenger RNA. When using this second target messenger RNA for protein expression to obtain the target recombinant human albumin, the expression efficiency of the host Pichia pastoris cells can be maximized, significantly improving the current synthesis efficiency of recombinant human albumin and greatly alleviating the problem of human albumin drug scarcity.
Owner:SHENZHEN PROTGEN LTD

Lipid nanoparticles comprising imidazolium-based cationic lipids

The present invention relates to compositions for delivering nucleic acids, in particular messenger RNA (mRNA), in vitro and in vivo into target cells and uses thereof. The present invention relates to a composition comprising (A) at least one nucleic acid and (B) at least one lipid nanoparticle (LNP) comprising: (i) at least one ionizable lipid; (ii) at least one phospholipid; (iii) at least one sterol, in particular a neutral sterol; (iv) at least one poly (ethylene glycol)-lipid (PEG-lipid); and (v) an imidazolium-based cationic lipid of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9, Y and A-are as defined in the specification. The invention also relates to a method for transfecting living cells in vitro or in vivo and to the use of said composition.
Owner:POLYPLUS TRANSFECTION SA

Pharmaceutical composition containing elastin and method of using the same

PendingKR1020260115928ADiseaseMessenger RNA
The present invention provides a pharmaceutical composition comprising an exosome encapsulating one or more cargo RNAs containing package RNA and one or more fusion proteins, wherein the nucleotide sequence of the package RNA is at least about 80%, about 85%, about 90%, about 95%, or about 100% identical to the nucleotide sequence of an elastin (ELN) gene or elastin messenger RNA (mRNA) also containing any isoform. Additionally, the present invention provides a method for treating an elastin deficiency-related disease in a subject using the pharmaceutical composition of the present invention.
Owner:진 컴퍼니 (피티와이) 리미티드

L-RNA aptamer-antisense oligonucleotide conjugates and uses thereof

An L-form ribonucleic acid (L-RNA) aptamer-antisense oligonucleotide (ASO) conjugate comprise the L-RNA aptamer, which comprises a ribonucleic acid sequence. The ASO comprises a deoxyribonucleic acid sequence selected from a group. A method of imaging amyloid precursor protein (APP) rG4 in a cell comprising transfecting the cell with a messenger RNA of APP, permeating the cell, contacting the permeated cell with a cyanine3 (Cy3) labeled APP nucleic acid probe and the L-RNA aptamer-ASO conjugate, and subjecting the product to fluorescence microscopy analysis to produce an image of the APP rG4 in the cell.
Owner:CITY UNIVERSITY OF HONG KONG

Pharmaceutical composition comprising elastin and method of use thereof

The present invention provides a pharmaceutical composition comprising an exosome encapsulating one or more cargo RNAs comprising a package RNA and one or more fusion proteins wherein the nucleotide sequence of the package RNA is at least about 80%, about 85%, about 90%, about 95% or about 100% identical to the nucleotide sequence of an elastin (ELN) gene or an elastin messenger RNA (mRNA) that also includes any isoforms. The present invention also provides a method of treatment of elastin deficient related illness in a subject using the pharmaceutical composition of the present inventin.
Owner:GENECO PTY LTD +1

Methods for purification of messenger RNA

The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized rnRNA to a denaturing condition, and purifying the rnRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and / or enzyme reagents used in in vitro synthesis.
Owner:TRANSLATE BIO INC

Process of preparing mrna-loaded lipid nanoparticles

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of combining a solution of preformed lipid nanoparticles with lipid nanoparticles encapsulating mRNA, resulting in a composition of increased potency of mRNA encoded protein expression in vivo.
Owner:TRANSLATE BIO INC

Cationic lipid compound

The present invention relates to lipid compounds, which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and / or their analogs, and / or lipid-conjugated polymers to form lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In some instances, the lipid nanoparticles are used to deliver nucleic acids, such as messenger RNA and / or antisense RNA. Methods of using such lipid nanoparticles to treat and / or prevent various diseases are also provided. In one embodiment, a compound having the structure of formula (I) is provided: or a salt or an isomer or an N-oxide thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Pharmaceutical compositions comprising one or more of the compounds of the foregoing structural formula (I) and a therapeutic and / or prophylactic agent are also provided. In some embodiments, the pharmaceutical composition further comprises one or more components selected from neutral lipids, charged lipids, steroids and lipid-conjugated polymers. Such compositions are useful for forming lipid nanoparticles for delivering therapeutic and / or prophylactic agents. In other embodiments, the present invention provides a method of administering a therapeutic and / or prophylactic agent to a subject in need thereof, the method comprising preparing a pharmaceutical combination of a lipid nanoparticle comprising a compound of structural formula (I) and a therapeutic and / or prophylactic agent, and delivering the composition to the subject.
Owner:GUANGZHOU ANOVENT PHARMACEUTICAL CO LTD

Modified mrna for multicellular transformation

PendingCN122376717ACancer cellMessenger RNA
Synthetic bacterial messenger RNA can be used to make autologous, allogeneic or direct nucleic acid cancer vaccines. Cancer cells are transfected in vitro or in vivo with mRNA obtained from DNA encoding immunogenic bacterial proteins. The immune response to cancer is generated by direct administration of the mRNA in vivo or administration of a vaccine made from cancer cells in vitro. Codon modification of the mRNA can optimize expression of the immunogenic polypeptide in cancer cells.
Owner:TUHELA BIOSCIENCES

Method for quantifying an amount of capped messenger RNA

Provided are a method for quantifying an amount of capped messenger RNA (mRNA) in an mRNA sample comprising contacting the mRNA with two or more of a nuclease, an alkaline phosphatase, and a polynucleotide kinase and separating the capped mRNA and the uncapped mRNA occurs using chromatography.
Owner:RECODE THERAPEUTICS INC

Methods, models, apparatuses, devices, and media for predicting messenger RNA stability

The present application relates to the technical field of biological information, and discloses a messenger RNA stability prediction method, model, device, equipment and medium, the method comprises the following steps: obtaining target sequence information of target messenger RNA; using the feature extraction module in the messenger RNA stability prediction model, at least two of the following target feature information is obtained based on the target sequence information: first sequence feature information, Kozak sequence feature information, Motif attention feature information and manual feature information; using the prediction head in the messenger RNA stability prediction model, predicting the stability of the target messenger RNA based on the target feature information. The present application predicts the mRNA stability by fusing the general sequence features of mRNA, the learnable position weight Kozak sequence features, the Motif attention features based on hash k-mer and the manual features, thereby improving the accuracy of mRNA stability prediction.
Owner:BEIJING YUEKANGKECHUANG PHARM TECH CO LTD

RNA formulations suitable for therapy

ActiveUS12667621B2DimerMessenger RNA
The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.
Owner:BIONTECH SE

VLP enteroviral vaccines

Aspects of the disclosure relate to compositions of messenger RNA vaccines and methods of administration thereof. Compositions provided herein include one or more RNA polynucleotides having an open reading frame encoding an Enterovirus capsid polyprotein and a protease. Compositions provided herein include one or more RNA polynucleotides having an open reading frame encoding an active product that modulates the expression, structure or function of at least one other RNA or product thereof. Compositions and methods provided herein relate to therapeutic treatment of gastrointestinal disease.
Owner:MODERNATX INC

Replicase cycling reaction (RCR) and the related RdRP-binding site designs thereof

ActiveUS12781274B2Messenger RNABinding site
This invention relates to a novel composition of RNA / mRNA medicines and / or vaccines produced by using Replicase / RNA-dependent RNA polymerase (RdRP)-mediated RNA Cycling Reaction (RCR). This RCR-amplifiable RNA / mRNA composition comprises at least a replicase / RdRP-binding site (RdRP-BS) in the 5′-end or 3′-end, or both, of a desired RNA sequence of interest, to form a self-amplifying RNA / mRNA (samRNA) platform. The samRNA platform so obtained is useful for designing and developing a variety of self-amplifying RNA / mRNA (samRNA) constructs, of which the desired RNA sequences may include, but not limited to, antisense oligonucleotide RNA (aRNA; ASO), small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA) / miRNA precursor (pre-miRNA), long non-coding RNA (lncRNA), and / or messenger RNA (mRNA), or a combination thereof. The present RdRP-BS designs in said samRNA are derived or modified from the identified RdRP-BS motifs of coronavirus (e.g. SARS-CoV-2-associated viruses) and / or hepatitis C virus (HCV) in either single-stranded or double-stranded conformation, or a combination thereof.
Owner:LIN SHI LUNG +1